Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.60 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13198066 | 0.81 | MAPK14 (0.65) | RAB9ANPC1KMT2APOLBBRAF | |
| SCHEMBL2379165 | 0.79 | HTT (0.52) | RAB9ANPC1KMT2APOLBMAPT | |
| SCHEMBL11729390 | 0.78 | KMT2A (0.72) | RAB9ANPC1KMT2APOLBMAPT | |
| SCHEMBL4619068 | 0.78 | RAB9A (0.64) | RAB9ANPC1KMT2APOLBCASP3 | |
| SCHEMBL13198009 | 0.74 | ABL1 (0.61) | RAB9ANPC1KMT2APOLBROCK2 | |
| SCHEMBL10450301 | 0.74 | MKNK1 (0.56) | KMT2ABRAFROCK2MAPTMEN1 | |
| SCHEMBL4620913 | 0.74 | TRPV1 (0.71) | RAB9ANPC1KMT2APOLBALDH1A1 | |
| SCHEMBL12298503 | 0.74 | EPHX2 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4432783 | 0.73 | IMPDH2 (0.65) | RAB9ANPC1KMT2APOLBROCK2 | |
| SCHEMBL2380290 | 0.73 | KDR (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1896461-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | Amgen Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | RAB9A 1962/4885NPC1 1163/4885KMT2A 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.